The study aimed to identify the maximum tolerated dose (MTD) for treating muscle invasive bladder cancer using image-guided adaptive radiation therapy while monitoring long-term clinical outcomes.
A total of 59 patients with specific stages of bladder cancer participated, with their tumors receiving doses ranging from 68 to 72 Gy, and the MTD was found to be 70 Gy.
Results showed that 5-year overall survival was 58%, and the bladder preservation rate was high at 89%, with minimal severe acute toxicities reported.
The study investigates how effective neoadjuvant chemotherapy (NAC) is for patients with localized muscle-invasive bladder cancer (MIBC) by using diffusion-weighted MRI (DWI) to analyze treatment response and long-term survival outcomes.
It involved 48 patients, using DWI to measure changes in tumor characteristics before and after NAC, and linking these changes to patient outcomes based on ADC values and response classifications.
Results showed that patients with a significant increase in ADC values after NAC had better survival rates, indicating that DWI metrics could predict treatment response and long-term outcomes effectively.